Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for ...

Continued Investment in Pipeline and Acquired Assets in 2026 to Fuel Long-Term GrowthReaffirms Full-Year 2025 Adjusted(1) Diluted EPS Guidance(2) and Revises Full-Year 2025 Revenue Guidance(2) to ...

The "Biocompatibility Testing Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering.Senior executives in healthcare face evolving challenges as ...

SAS predicts the path for data and AI to reshape how the industry discovers, treats and delivers careMarlow, UK (December 16, 2025) – As we step into 2026, the AI and analytics story for health care ...

Global life sciences supply chain conference LogiPharma has announced a brand-new series of interactive formats for 2026 under the leadership of incoming event director, Ben Sharples.“This year’s ...

Lindus Health and Quotient Sciences Partner to Accelerate Drug Development from First-in-Human to Pivotal Trials BOSTON, Dec.16, 2025 – Lindus Health, the "anti-CRO" running radically faster, more ...

Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, today announced FDA approval of a Phase II clinical trial ...

PARIS, FRANCE / ACCESS Newswire / December 16, 2025 / One year after deploying CaloPix®, the digital pathology platform developed by Tribun Health, NOVO Hospital (Val-d'Oise, France) reports clear, ...

GERMANTOWN, MD AND CHICAGO, IL / ACCESS Newswire / December 16, 2025 / uBriGene Biosciences, a leading global lentivirus CDMO specializing in Advanced Therapy Medicinal Product (ATMP) GMP development ...

A New Era of Smart Access, Enhanced Living, and Turnkey Revenue Opportunities.TORONTO--(BUSINESS WIRE)--As resident expectations evolve and buildings compete on experience, Snaile, Canada’s award ...

Today, Latent Labs announces Latent-X2, a frontier AI model that can design drug-like biologics without iteration. Drug hunters can use Latent Lab's AI platform, built on Latent-X2, to access ...

CTT Pharmaceutical Holdings, Inc. is pleased to announce that a peer-reviewed scientific paper has been published in the journal of Drug Delivery and Therapeutics, authored by our scientist Dr.